EVTA Stock Chart & Stats
€2.62
€0.06(1.45%)
At close: 4:00 PM EST
€2.62
€0.06(1.45%)
Day’s Range― - ―
52-Week Range€1.55 - €3.78
Previous CloseN/A
Volume5.00K
Average Volume (3M)54.00
Market Cap
€613.64M
Enterprise Value€821.79
Total Cash (Recent Filing)€445.23M
Total Debt (Recent Filing)€387.87M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 13, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding355,819,120
10 Day Avg. Volume156
30 Day Avg. Volume54
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.46Price Target Upside-6.27% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)€622.16M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity PositionA large cash buffer (EUR ~445m) plus an expected ~USD100m inflow materially reduces short-term refinancing risk and funds the Horizon transformation. This strengthens the company's ability to invest in commercialization, absorb restructuring costs, and support partner programs over the next 2–6 months.
Proprietary Platforms & Co-owned PipelineProprietary discovery platforms and a large portfolio of co-owned assets create durable competitive advantages: recurring partnership demand, longer customer relationships and potential future milestone/royalty streams that provide optionality and strategic upside beyond fee-for-service revenue.
Improving Commercial Leading IndicatorsSustained improvement in proposals, faster turnaround and higher net orders indicate a strengthening sales funnel. If these trends persist, they should support higher contracted revenues and utilization over coming quarters, improving revenue visibility and helping margin recovery as Horizon actions take effect.
Bears Say
Declining Revenue & Weak MarginsSustained revenue declines and deeply negative margins reflect structural earnings weakness. Unless top-line stabilizes and higher-margin services scale, losses will persist, limiting the company's ability to generate durable profits in the 2–6 month horizon despite cost measures.
Negative Free Cash Flow And Volatile Cash GenerationNegative and volatile free cash flow constrains self-funded investment and increases reliance on asset sales, milestone receipts or external financing. This reduces resilience during transformation and could limit reinvestment in commercial growth or capacity even if operational indicators improve.
Large Restructuring Provisions & Execution RiskMaterial restructuring charges raise near-term cash outflows and execution risk: realizing targeted €75m run‑rate savings requires successful site consolidations and workforce changes, which can disrupt delivery and client relationships if not executed cleanly over the next several quarters.
Evotec AG News
EVTA FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was €1.55 and its highest was €3.78 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is €613.64M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Aug 13, 2026 which is in 17 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Overvalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.04.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,120 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in DE:EVTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.46 (-6.27% Downside)
€2.46 (-6.27% Downside)
Blogger Sentiment
Bullish
DE:EVTA Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVTA Company Deck
EVTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: significant near-term financial weakness driven by the nonrecurrence of a large prior-year license payment, FX headwinds, negative adjusted EBITDA and substantial restructuring charges contrasted with clear strategic actions and early signs of commercial stabilization. Management initiated the Horizon transformation, added experienced leadership, pointed to improving commercial leading indicators (higher proposal activity, faster turnaround, fewer change orders and net sales orders +15% YoY), and maintained full-year guidance while highlighting expected structural savings (~EUR 75m run-rate by end-2027, with ~20–30% in 2026) and an anticipated USD 100m cash inflow in Q2. Given material near-term negatives balanced against concrete transformation moves, underlying Just momentum (ex-Sandoz) and improving D&PD indicators, the overall tone is cautious but constructive.View all DE:EVTA earnings summariesEVTA Stock 12 Month Forecast
Average Price Target
€2.46
▼(-6.27% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―